PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Exp Cell Res. Author manuscript; available in PMC 2013 May 15.
Published in final edited form as:
PMCID: PMC3336874
NIHMSID: NIHMS367872

Role of FGF23 in Vitamin D and Phosphate Metabolism: Implications in Chronic Kidney Disease

Abstract

FGF23 is a bone-derived hormone that regulates systemic phosphate homeostasis, vitamin D metabolism and α-klotho expression through a novel bone-kidney axis. FGF23 inhibits renal tubular reabsorption of phosphate through mechanisms independent of PTH as well as reduces circulating 1, 25(OH)2D through its dual effects to suppress Cyp27b1 production and to stimulate Cyp24 catabolism of 1,25(OH)2D. 1,25(OH)2D and other factors regulating bone remodeling/mineralization are the major physiological regulators of FGF23 expression. FGF23 also suppresses the gene transcription of α-klotho by the kidney, which exists as a membrane and soluble protein. Membrane Klotho acts as a coreceptor for and dictates organ specificity of FGF23, whereas soluble Klotho act as an endocrine factor that regulates activity of cell surface glycoproteins and receptors in multiple tissues. Elevated FGF23 levels are responsible for several hereditary and acquired hypophosphatemic rickets disorders. FGF23 and Klotho deficiency have similar phenotypes characterized by hyperphosphatemia, elevated 1,25(OH)2D and tumoral calcinosis. FGF23 levels progressively increase during chronic kidney disease (CKD). FGF23 has been proposed to be the initial adaptive response leading to reductions in 1,25(OH)2D and secondary hyperparathyroidism (HPT) in CKD. The overall biological effect of this initial step may be to orchestrate a coordinated adaptation to protect the organism from the adverse effects of excess phosphate retention. The second step involves the effects of PTH on bone remodeling that further stimulates FGF23 production through both direct and indirect mechanisms related to alterations in extracellular matrix factors. PTH further amplifies FGF23 expression in later stages of CKD to compensate for the increased phosphate efflux from bone caused by excessive bone turnover. While many aspects of the regulation and functions of FGF23 remain to be established, the idea that FGF23 hormone is the initial adaptive hormonal response in CKD that suppresses 1,25(OH)2D, reduces gastrointestinal calcium and phosphate absorption and leads to a secondary HPT represents a paradigm shift in the conceptualization of the pathogenesis of secondary hyperparathyroidism. In addition, the prevalent thought that CKD is a functional “vitamin D deficient state” requiring therapy with 1,25(OH)2D analogues is challenged by effects of FGF23 to potentially lower both 25(OH)D and 1,25(OH)D by induction of Cyp24-mediated degradation. Finally, increments in FGF23 are associated with increased cardiovascular mortality in CKD. Whether these effects represent direct effects of FGF23 or represent a marker of other abnormalities in CKD remain to be determined.

Keywords: 1,25(OH)2D; bone; kidney; calcium; osteoblasts; osteocytes; cyp27b1; cyp24; klotho

Overview of FGF23

FGF23 is a ~32 kDa secreted protein, predominately expressed in osteoblasts and osteocytes (45, 51, 84, 103), that principally targets receptor complexes consisting of FGFR 1,3 or 4 and the transmembrane β glucuoronidase, α-Kl (37, 43, 92, 105) in the kidney to inhibit renal phosphate reabsorption by decreasing Na-dependent co-transporters and to suppress circulating 1,25(OH)2D levels by inhibiting Cyp27b1 (which converts 25(OH)D to 1,25(OH)2D) and by stimulating the catabolism of 1,25(OH)2D by activating the 24-hydroxylase (Cyp24) (3, 23, 7778, 80, 90, 101). Elevated FGF23 causes several hereditary (including, XLH, ADHR, and ARHR) and acquired (e.g., MAS and TIO) hypophosphatemic disorders. In contrast, reductions in FGF23 lead to tumoral calcinosis, characterized by hyperphosphatemia, increased 1,25(OH)2D and soft tissue calcifications (62) (46, 6263)]. FGF23 is markedly elevated in chronic kidney disease (CKD)(54), where FGF23 regulation and function remain to be fully characterized.

Physiological regulation FGF23

FGF23 is regulated by both systemic and local factors. FGF23 acts as a counter regulatory factor for 1,25(OH)2D (49) and participates in a bone-kidney feedback loop, consisting of 1,25(OH)2D stimulation of FGF23 production in bone and FGF23 suppression of 1,25(OH)2D production by the kidney (49). A less well characterized feedback loop exists that involves stimulation of FGF23 expression in bone when FGF23 signaling in the kidney is blocked either through ablation of FGFR or α-Kl (50, 92). PTH regulation of FGF23 is controversial. FGF23 is elevated by activating PTH/PTHrp receptor and GNAS mutations (8). In addition, FGF23 is elevated in mice overexpressing a constitutively active PTH receptor in osteocytes (Dmp1-caPTHR1) and a PTH directly stimulates FGF23 expression in UMR 106 osteoblasts (41, 6768). FGF23 is also increased in some animal models of excess PTH (29, 41, 76). The ability of PTH to stimulate FGF23, however, is context dependent. For example, PTH failed to directly stimulate FGF23 production or FGF23 promoter activity in Ros17/2.8 osteoblasts in vitro (49), or in calvarial cultures ex vivo (73). In other circumstances PTH had no effect on FGF23 expression (73, 75). The mechanism underlying the variable effects of PTH on FGF23 gene expression is not known.

There is also emerging evidence linking bone metabolism with FGF23 regulation. FGF23 appears to coordinate renal phosphate handling to match bone mineralization/remodeling (12, 47, 51, 71), which impact upon the influx and efflux of calcium and phosphate from bone (64, 76, 94) (i.e., increased bone avidity for phosphate→ decreased FGF23, and decreased phosphate uptake or increased efflux due to increased bone remodeling→increased FGF23) (17, 62) (8). There are numerous examples of single gene mutations leading to alterations in bone remodeling leading to increased FGF23 (33, 49, 63). Dmp1, Phex and ENPP1 mutations which block bone mineralization also lead to increased FGF23 production by osteocytes (27, 48), whereas nutritional osteomalacia is associated with decreased FGF23 that paradoxically increases after healing of bone (93). OPG- or alendronate-mediated inhibition of bone turnover that limit phosphate influx to bone also increase FGF23 (75). Bone remodeling/mineralization may be linked to FGF23 through multiple pathways, including both canonical FGFR and integrative nuclear FGF receptor 1 signaling and Wnt signaling (62). Leptin, estrogens and glucocorticoids also coordinately regulate FGF23 and bone remodeling (91). Although FGF23 is a phosphate regulating hormone, tight coupling between changes in serum phosphate and FGF23 are not present (49, 52). Some studies have failed to observe changes in FGF23 in healthy individuals in response to either low or high phosphate diets (40, 57). In contrast, other studies have shown that alterations in dietary phosphate lead to differences in FGF23, albeit after a lag time of up to 1 week (1, 9, 13, 55, 60, 96). The effects of phosphate on FGF23 are also be modulated by the vitamin D status, since increasing dietary phosphorus does not increase FGF23 in the absence of the VDR (80). Phosphate may indirectly regulate FGF23 by affecting bone mineralization (49, 52).

Physiological functions of FGF23

Excess FGF23 causes hypophosphatemia, suppression of 1,25(OH)2D, and rickets/osteomalacia (2, 15, 39, 78, 80). Loss of Fgf23 function results in hyperphosphatemia, excess 1,25(OH)2D, and soft tissue calcifications (6, 28, 38, 51, 77, 8283). FGF23 regulation of cellular function in target tissues is mediated by binding to FGF receptor/Klotho complexes. α-Klotho is an obligate co-receptor for FGF23 and the tissue restricted actions of FGF23 are dictated by the sites of the transmembrane, full-length form of α-Klotho. These physiological effects of FGF23 and the localization of α-Klotho in the kidney, suggest that FGF23 principally targets the kidney. In the kidney, FGF23 inhibits renal phosphate reabsorption by decreasing Npt2 co-transporters and suppresses 1,25(OH)2D levels by inhibiting Cyp27b1 and stimulating Cyp24 (3, 23, 7778, 80, 90, 101). FGFR 1, 3 and 4 appear to be targets for FGF23 in the kidney, the FGFR 3 and 4 playing a greater role in regulation of vitamin D metabolism and FGFR1 in the regulation of phosphate reabsorption (42). Klotho is known to be present in the distal tubule and its expression in the proximal tubule, sites of phosphate reabsorption and vitamin D metabolism, remains uncertain. Consequently, a distal to proximal feedback loop has been postulated to explain the proximal tubular actions of FGF23.

Low expression of α-klotho is also reported in the pituitary gland, placenta, skeletal muscle, urinary bladder, aorta, pancreas, testis, ovary and colon (4, 36), where the function of FGF23 is not certain. Knock-in of the lacZ gene downstream of the translational initiation codon of α-klotho also shows expression of α-klotho in the parathyroid gland (5), and sinoatrial cells of the heart (79, 87). In addition, Klotho, itself is released into the circulation by ectodomain shedding of the membrane Klotho or by secretion of an alternatively spliced form of Klotho that lacks the transmembrane domain. Secreted Klotho inhibits insulin- and IGF-1-induced autophosphorylation of insulin receptor and IGF-1 receptor in vitro and Klotho-deficient mice exhibit hypoglycemic, hypoinsulinemic, and increased insulin sensitivity, as well as other abnormities leading to decreased survival (35). Klotho production is markedly decreased in CKD (32). Thus, FGF23 may affect other organs indirectly through its affects on circulating Klotho levels, analogous to its effects on serum 1,25(OH)2D concentrations. It has also been suggested that Klotho regulates phosphate absorption independently of FGF23. Secreted Klotho is filtered by the glomerulus and taken up by the proximal tubule where it has been shown to decrease the cell surface expression of the sodium-phosphate transporter (24). However, since FGF23 decreases the Klotho gene transcription; the phosphaturic actions of FGF23 are associated with decreased Klotho expression and attenuation of its direct phosphaturic actions, which is physiologically incongruous. Increased circulating levels of FGF23 are associated with increased mortality in patients with CKD (19) (14) and may be a cardiovascular disease risk factor in the general population(53). These observations and the finding of membrane Klotho in other tissues as well as the endocrine functions of secreted Klotho, suggest that FGF23 may have both direct and indirect actions on other biological processes other than regulation of phosphate and vitamin D metabolism. Thus, FGF23 effects on cardiovascular mortality could potentially represent a direct effect of FGF23 on cardiac tissues. Further studies are needed to elucidate the potential direct and indirect mechanisms that might explain the association between FGF23 and mortality.

FGF23 effects on the parathyroid gland (PTG) are controversial (36, 44). FGF23 directly suppresses PTH mRNA expression in vitro and decreases serum PTH in vivo (4), however, FGF23 does prevent the development of hyperparathyroidism (HPT) in any clinical circumstance and there is a strong association between elevated FGF23 levels and the severity of HPT in CKD and other disorders (92), suggesting FGF23 may promote the development of HPT (36, 44, 92). Recent studies indicate resistance to FGF23 develops in uremic PTGs due to down-regulation of Kl and FGFR expression (16, 34), which may explain this paradox. The mechanism of this down-regulation is not known, but FGF23 is known to decrease Klotho expression in the kidney. Alternatively, there is some indirect data that FGF23 may stimulate PTG proliferation leading to hyperplasia and refractory HPT(100).

Role of FGF23 in CKD-Mineral Bone Disorder (CKD-MBD)?

The pathogenesis of CKD is traditionally viewed from the perspective of the PTH-Vitamin D axis, and current treatments focus on suppressing PTH with active vitamin D analogues (99), which can raise serum calcium and phosphate concentrations (89) and further stimulate FGF23 (7, 19, 65, 104). Cross-sectional studies in humans show early FGF23 elevations in CKD in proportion to reduced GFR (18) and is associated with reductions of 1,25(OH)2D and increments in Cyp24 (20). FGF23 is markedly elevated in ESRD (18, 25, 97), where levels correlate with the degree of hyperphosphatemia (25, 97), predict refractory HPT in some studies (34) and is associated with increased mortality (86). There are many important questions about FGF23 in CKD that remain to be answered (102).

What comes first, FGF23 and PTH?

Cross sectional studies in CKD have found that increased FGF23 concentration is an early marker of CKD (14, 18, 95). FGF23 is positively correlated with parathyroid hormone and phosphate concentrations and negatively correlated with 1,25(OH)2D, estimated glomerular filtration rate, and tubular phosphate reabsorption. Several longitudinal studies in animal models of CKD show a near simultaneous increase in FGF23 and PTH and efforts to establish which comes first gives opposite conclusions. This has led to two competing hypotheses.

There is compelling data to support the scenario that FGF23 is the initial event in CKD leading to reductions in 1,25(OH)2D and secondary increments in PTH. Analysis of the expression of enzymes that regulate vitamin D metabolism, Cyp27b1 and Cyp24, suggest a pattern most consistent with an effect of FGF23 in CKD (21). In a rat model of anti-GBM nephritis treatment with a neutralizing anti-FGF23 antibody (20) increased serum 1,25(OH)2D and Cyp27b1 and reduced Cyp24 as well as suppressed PTH. Ttreatment with paracalcitol further elevates FGF23 and suppresses PTH in ESRD (85).

On the other hand, there is equally compelling evidence for a PTG-bone feedback loop, where, FGF23 directly suppresses PTH mRNA expression in vitro and decreases serum PTH in vivo (4) and PTH stimulates FGF23 expression in bone in CKD (29, 31, 66, 76). The most compelling are studies reported by Lavi-Moshayoff et al, which found that PTH increases FGF23 gene expression and mediates the high-FGF23 levels of in a 0.75% adenine 1.5% high-phosphorus diet-induced CKD model in rats (41). In these studies early PTX prevented the increase in FGF23 observed in rats with adenine-induced renal failure without PTX. These investigators also found that continuous PTH administration at high doses (50 ug/kg/day) stimulated FGF23 production in both mice and PTH also stimulated FGF23 expression in UMR-106 osteoblasts cultures. However, FGF23 does prevent the development of HPT in any clinical circumstance and there is a strong association between elevated FGF23 levels and the severity of HPT in CKD and other disorders (36, 44, 92). To reconcile these discrepancies this hypothesis proposes that resistance to FGF23-mediated suppression of PTH develops in CKD, permitting elevations in PTH in spite of concurrent increments in FGF23 (4, 16, 34),

Several observations fail to support the hypothesis that PTH directly regulates FGF23 hypothesis. First, there are important limitations to the high dietary phosphate-adenine model of “CKD”, including its rapid onset, early hypocalcemia (likely induced by high phosphate diet), and the failure to observe reductions of 1,25(OH)2D (whereas reduction in 1,25(OH)2D is the hallmark of CKD in humans. These conflicting findings highlight the importance other factors, such as calcium, dietary phosphate intake, bone turnover, vitamin D status, which can confound establishing cause-and-effect relationships. Second, PTH does not directly stimulate FGF23 production or FGF23 promoter activity in osteoblasts in vitro (49), or in calvarial cultures ex vivo (73), and PTH administration has been shown to suppress FGF23 in normal mice (75). FGF23 is also not elevated in patients with primary HPT (88). Second, in studies showing a relationship between PTH and FGF23, the increase in FGF23 could be indirectly due to the effects of PTH to stimulate 1,25(OH)2D (21, 29, 74). Nevertheless, the finding of PTH regulation of FGF23 suggests a modified traditional hypothesis where increased PTH levels (in response to hypocalcemia, phosphate retention or calcitriol deficiency (11)) secondarily stimulates FGF23.

Do alterations in bone remodeling/mineralization explain the variable effects of PTH on FGF23?

Another possibility is that PTH induction of high bone turnover (osteitis fibrosa) might lead to increased production of FGF23 in peritrabecular osteoblasts, similar to McCune-Albright syndrome (MAS), caused by activating mutations of Gαs (30, 69, 81). The pattern of FGF23 expression in bone of Col4a3 null mice resembles MAS (69) (see Preliminary studies). Excessive bone resorption in excess of bone formation, as occurs with continuous PTH administration, resulted in increased FGF23, whereas the administration of intermittent PTH that leads to a net increase in bone formation and increased bone mass resulted in reductions in FGF23(75). Targeted disruption of Kif3a in osteoblasts using OC-Cre leads to a 3-fold increase in FGF23 in association with low turnover osteopenia from disruption of the Ihh pathway (which is linked to PTHrp and PTHR1 (22)). PTH-stimulated FGF23 expression was also inhibited by disruption of Wnt-signaling with sclerostin, consistent with an indirect paracrine rather than direct regulation of FGF23 by PTH (41).

Does bone metabolism account for the variable effects of phosphate in regulating FGF23?

Serum phosphate levels positively correlate with elevations in FGF23 levels in ESRD (97), but phosphate restriction failed to lower elevated FGF23 levels in patients with CKD (26). A study in CKD patients with elevated FGF23 randomized to either sevelamer or calcium carbonate found that urinary phosphorus excretion and PTH decreased in both treatment groups, but FGF23 only decreased in the sevelamer arm, a binder known to provide an acidic load which may alter bone phosphate flux (59). A small reduction in FGF23 (84 vs 61 pg/ml) has been reported in a low phosphate vegetarian diet in CKD (55). In an adenine induced CKD rat model, sevelamer prevented the increase in PTH and FGF23, but the effects were delayed, requiring 2-weeks to achieve reductions in FGF23, whereas correction in hyperphosphatemia occurred rapidly (56). A high phosphorus diet was shown to enhance, and a low phosphorus diet to inhibit, the elevation of serum FGF23 levels in 5/6 nephrectomized rats, but this result was obtained after 4 weeks of dietary treatment (72). Phosphate effects on bone mineralization could account for the delayed effects of phosphate on FGF23 expression, involving pathways similar to those affected by Phex, Dmp1, ENPP1 mutations (vide supra).

Integrated Hypothesis of FGF23 Regulation and Function in CKD (Fig 1)

Figure 1
Integrative physiology of FGF23. FGF23 can exert multiple direct and indirect effects on a wide range of biological functions and is involved in complex endocrine networks involving 1,25(OH)2D, Klotho, and PTH endocrine factors. FGF23 participates in ...

A two-step hypothesis may reconcile the conflicting data regarding the respective roles of FGF23 and PTH in the pathogenesis of abnormal mineral metabolism in CKD. The first part of the hypothesis integrates current knowledge of the FGF23 -Vitamin D endocrine loop, whereas the later proposition incorporates emerging knowledge regarding the role of intrinsic bone matrix-derived factors in the regulation of FGF23. There is evidence to support that that increased FGF23 (due to impair renal phosphate clearance, reduced GFR or some other signal from kidney to bone feedback loop) is the initial adaptive response in CKD. FGF23 leads to a decrease in both 25(OH)D and 1,25(OH)2D due Cyp24-mediated catabolism and the resulting reduction of 1,25(OH)2D leads to secondary increments in PTH, due to impaired calcium absorption by the intestines and loss of direct effects of 1,25(OH)2D on PTG and bone (i.e., a FGF23-mediated functional vitamin D deficiency). The next step involves PTH actions to restore calcium balance by stimulating bone remodeling, leading to both increased bone calcium and phosphate efflux, and by actions on the kidney to increase Cyp27b1 and reduce renal calcium excretion. PTH-mediated effects on mineralization/bone remodeling leads to local alterations in the bone matrix that further amplify FGF23 expression. The additional FGF23 facilitates the renal excretion of phosphate released from bone. In addition, FGF23, through reductions in 1,25(OH)2D and soluble secreted Klotho, may have additional indirect effects on multiple other organ systems to explain the associations between elevated FGF23 and adverse cardiovascular outcomes and mortality.

Clinical Implications in CKD-MBD and Areas of Further Study

Revising the “vitamin D deficient” hypothesis of CKD-MBD pathogenesis

Contradictory and competing hypotheses and uncertainties about the cause-and-effect relationship between FGF23, PTH and 1,25(OH)2D are confounding the understanding of the pathogenesis and treatment of CKD-MBD. It makes a big difference whether FGF23 is the initial event leading to increased PTH or is secondary to increments in PTH. If the two step hypothesis is correct, it may be possible to separately focus interventions on different mechanisms leading to increased FGF23 at different stages of CKD. In this conceptual framework, early CKD does not represent a true “vitamin D deficient” state; rather FGF23-mediated suppression of circulating 1,25(OH)2D levels is an adaptive response, which protects against hyperphosphatemia through reduction of 1,25(OH)2D’s effects on gastrointestinal phosphate absorption and by increasing PTH, which acts in concert with FGF23 to stimulate phosphaturia. On the other hand, late stages of CKD and in ESRD, the dominant stimulus for FGF23 elevations may be bone remodeling, leading to treatments that alter the local factors stimulating

Novel and more rational treatments of CKD-MBD

If this hypothesis is correct, FGF23 may be an early bi-omarker for earlier interventions. In addition, treatment approaches to prevent the elevations of FGF23 may become the initial therapeutic focus, but may differ depending on the stage of CKD. Since calcitriol increases FGF23 (a vicious cycle), calcitriol sparing therapies may be warranted, such as combined low dose paracalcitol and calcimimetics, which lowers FGF23 levels in ESRD patients (9899). Moreover, if the reductions in 1,25(OH)2D is due to increased Cyp24 rather than decreased Cyp27b1, approaches to either inhibit Cyp24 selectively or block FGFR3 and 4 selectively may be devised, which correct the FGF23-mediated abnormal vitamin D metabolism without affecting the phosphaturic actions of FGF23. Increased catabolism of 25(OH)D by Cyp24 would also explain the unexpected high prevalence of low 25(OH)D levels and the relative refractoriness of patients with CKD to ergocalciferol and cholecalciferol treatment. There is an emerging paradox that treatment with active vitamin D analogues is associated with improved survival, yet vitamin D analogues also increase serum phosphate and FGF23 levels, which may contribute to accelerated calcifications and increased mortality (58). Since most patients with ESRD receive therapy with active vitamin D analogues and there have been no prospective clinical trials comparing treatment paradigms that do not use calcitriol analogues, it is not known whether the current standard of care is optimal. Knowledge that treatment with active vitamin D analogues further increases FGF23, which is independently associated with increased mortality, may result in treatment strategies that reduce FGF23, which may include normalization of bone remodeling/mineralization.

Redefining the implications of vitamin D levels below the normal range

CKD is more prevalent in elderly adults than is detected by serum creatinine. If FGF23 elevations due to CKD are contributing to the low levels of 25(OH)D in elderly patients, future translational may need to distinguish FGF23-mediated reductions from true nutritional deficiencies. This may require assessing FGF23 and/or 24,25(OH)2D levels to interpret low 25(OH)D levels (e.g., true deficiency or increased catabolism secondary to increased FGF23 in subclinical CKD). This would add a new perspective to the existing uncertainties regarding the definition of vitamin D insufficiency and effects of vitamin D supplementation (70).

Summary and Conclusions

The discovery of FGF23 expression by osteoblasts/osteocytes has revealed the “endocrine functions” of bone in the regulation of phosphate and vitamin D metabolism. In addition, bone may have other endocrine functions to regulate insulin secretion and glucose metabolism that are mediated by the release of decarboxylated osteocalcin (Ocn) by bone resorption. Ocn is proposed to target receptors, such as GPRC6A, located in β-cells and peripheral tissues to regulate insulin secretion and insulin sensitivity (10, 61). Thus, the skeleton may play an important role in the integrative physiology of vitamin D, phosphate and “energy metabolism”. Assessment of the circulating levels of bone derived hormones may prove to have diagnostic utility and knowledge of the regulator factors controlling their secretion may provide new therapeutic opportunities, particular if systemic abnormalities associated with metabolic bone diseases, such as vascular calcifications and cardiovascular diseases, are mediated by these bone-derived hormones. Maintenance of normal bone remodeling and mineralization may not only be important to skeletal strength but to the bodies overall health.

Acknowledgments

This work was supported by the NIH grant number 2RO1AR045955.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Bibliography

1. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91:3144–3149. [PubMed]
2. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145:5269–5279. [PubMed]
3. Beckman MJ, Tadikonda P, Werner E, Prahl J, Yamada S, DeLuca HF. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry. 1996;35:8465–8472. [PubMed]
4. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007;117:4003–4008. [PMC free article] [PubMed]
5. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro OM, Mohammadi M, Sirkis R, Naveh-Many T, Silver J. The parathyroid is a target organ for FGF23 in rats. J Clin Invest. 2007 [PMC free article] [PubMed]
6. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet. 2005;14:385–390. [PubMed]
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218. [PubMed]
8. Brown WW, Juppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL. Hypophosphatemia with Elevations in Serum Fibroblast Growth Factor 23 in a Child with Jansen’s Metaphyseal Chondrodysplasia. J Clin Endocrinol Metab. 2009;94:17–20. [PubMed]
9. Burnett SA, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21:1187–1196. [PubMed]
10. Clemens TL, Karsenty G. The osteoblast: an insulin target cell controlling glucose homeostasis. J Bone Miner Res. 2011;26:677–680. [PubMed]
11. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, Sarro F, Valdivielso JM, Fernandez E. Mineral metabolism parameters throughout chronic kidney disease stages 1–5--achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22:1171–1176. [PubMed]
12. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006;38:1310–1315. [PMC free article] [PubMed]
13. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90:1519–1524. [PubMed]
14. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18:2600–2608. [PubMed]
15. Fukumoto S, Yamashita T. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens. 2002;11:385–389. [PubMed]
16. Galitzer H, Ben-Dov IZ, Silver J, Naveh-Many T. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int. 77:211–218. [PubMed]
17. Goebel S, Lienau J, Rammoser U, Seefried L, Wintgens KF, Seufert J, Duda G, Jakob F, Ebert R. FGF23 is a putative marker for bone healing and regeneration. J Orthop Res. 2009 [PubMed]
18. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215. [PubMed]
19. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584–592. [PMC free article] [PubMed]
20. Hasegawa H, Nagano N, Urakawa I, Yamazaki Y, Iijima K, Fujita T, Yamashita T, Fukumoto S, Shimada T. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78:975–980. [PubMed]
21. Helvig CF, Cuerrier D, Hosfield CM, Ireland B, Kharebov AZ, Kim JW, Ramjit NJ, Ryder K, Tabash SP, Herzenberg AM, Epps TM, Petkovich M. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int. 2010;78:463–472. [PubMed]
22. Hirai T, Chagin AS, Kobayashi T, Mackem S, Kronenberg HM. Parathyroid hormone/parathyroid hormone-related protein receptor signaling is required for maintenance of the growth plate in postnatal life. Proc Natl Acad Sci U S A. 2011;108:191–196. [PubMed]
23. Hoenderop JG, Chon H, Gkika D, Bluyssen HA, Holstege FC, St-Arnaud R, Braam B, Bindels RJ. Regulation of gene expression by dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1 alpha-hydroxylase knockout mice. Kidney Int. 2004;65:531–539. [PubMed]
24. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, Lanske B, Shawkat Razzaque M, Rosenblatt KP, Baum MG, Kuro OM, Moe OW. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. Faseb J. 2010 [PubMed]
25. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int. 2004;65:1943–1946. [PubMed]
26. Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, Juppner H, Wolf M. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2010 [PMC free article] [PubMed]
27. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24:948–955. [PubMed]
28. Kato K, Jeanneau C, Tarp MA, Benet-Pages A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006;281:18370–18377. [PubMed]
29. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M, Nishizawa Y. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol. 2007;18:2683–2688. [PubMed]
30. Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, Goto H, Ohashi H, Koyano HM, Mochizuki R, Miki T, Inaba M, Nishizawa Y. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci. 2006;78:2295–2301. [PubMed]
31. Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, Tahara H, Goto H, Miki T, Ishimura E, Sugimoto T, Ishikawa T, Inaba M, Nishizawa Y. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2006;154:93–99. [PubMed]
32. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001;280:1015–1020. [PubMed]
33. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK. 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol. 2005;289:G1036–1042. [PubMed]
34. Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 77:292–298. [PubMed]
35. Kuro-o M. Klotho. Pflugers Arch. 2010;459:333–343. [PubMed]
36. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51. [PubMed]
37. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120–6123. [PMC free article] [PubMed]
38. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE. Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology. 2005;146:3883–3891. [PubMed]
39. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087–3094. [PubMed]
40. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int. 2003;64:2272–2279. [PubMed]
41. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol. 2010;299:F882–889. [PubMed]
42. Li H, Martin A, David V, Quarles LD. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol Metab. 2011;300:E508–517. [PubMed]
43. Li H, Martin AC, David V, Quarles LD. Compound Deletion of FGFR3 and FGFR4 Partially Rescues the Hyp Mouse Phenotype. Am J Physiol Endocrinol Metab. 2010 [PubMed]
44. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell structure and function. 2004;29:91–99. [PubMed]
45. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem. 2003;278:37419–37426. [PubMed]
46. Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol. 2007;18:1637–1647. [PubMed]
47. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD. Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol. 2007;192:261–267. [PMC free article] [PubMed]
48. Liu S, Tang W, Fang J, Ren J, Li H, Xiao Z, Quarles LD. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol. 2009;23:1505–1518. [PubMed]
49. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305–1315. [PubMed]
50. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD. FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol. 2008;19:2342–2350. [PubMed]
51. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab. 2006;291:E38–49. [PubMed]
52. Mirams M, Robinson BG, Mason RS, Nelson AE. Bone as a source of FGF23: regulation by phosphate? Bone. 2004;35:1192–1199. [PubMed]
53. Mirza MA, Alsio J, Hammarstedt A, Erben RG, Michaelsson K, Tivesten A, Marsell R, Orwoll E, Karlsson MK, Ljunggren O, Mellstrom D, Lind L, Ohlsson C, Larsson TE. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011;31:219–227. [PubMed]
54. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney international. 2006;69:1945–1953. [PubMed]
55. Moe SM, Zidehsarai MP, Chambers MA, Jackman LA, Radcliffe JS, Trevino LL, Donahue SE, Asplin JR. Vegetarian Compared with Meat Dietary Protein Source and Phosphorus Homeostasis in Chronic Kidney Disease. Clin J Am Soc Nephrol. 2010 [PubMed]
56. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int. 2006;69:531–537. [PubMed]
57. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E. Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int. 2006;70:2141–2147. [PubMed]
58. O’Neill WC, Lomashvili KA. Recent progress in the treatment of vascular calcification. Kidney Int. 2010;78:1232–1239. [PMC free article] [PubMed]
59. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010;5:286–291. [PubMed]
60. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology. 2005;146:5358–5364. [PubMed]
61. Quarles LD. The bone and beyond: ‘Dem bones’ are made for more than walking. Nat Med. 2011;17:428–430. [PubMed]
62. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008;118:3820–3828. [PMC free article] [PubMed]
63. Quarles LD. Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest. 2003;112:642–646. [PMC free article] [PubMed]
64. Quarles LD, Drezner MK. Effects of etidronate-mediated suppression of bone remodeling on aluminum-induced de novo bone formation. Endocrinology. 1992;131:122–126. [PubMed]
65. Razzaque MS, St-Arnaud R, Taguchi T, Lanske B. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant. 2005;20:2032–2035. [PubMed]
66. Rhee Y. FGF23 Gene Expression Is Upregulated by PTH Receptor Activation in Osteocytes In vitr and In vivo: A parathyroid-Bone Link Influencing the Endocrine Function of Osteocytes. J Bone Miner Res; ASBMR 31st Annual Meeting; 2009. p. A09001860.
67. Rhee Y, Allen MR, Condon K, Lezcano V, Ronda AC, Galli C, Olivos N, Passeri G, O’Brien CA, Bivi N, Plotkin LI, Bellido T. PTH receptor signaling in osteocytes governs periosteal bone formation and intra-cortical remodeling. J Bone Miner Res. 2010 [PMC free article] [PubMed]
68. Rhee Y, Bivi N, Farrow E, Lezcano V, Plotkin LI, White KE, Bellido T. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone. 2011 [PMC free article] [PubMed]
69. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112:683–692. [PMC free article] [PubMed]
70. Rosen CJ. Clinical practice. Vitamin D insufficiency. N Engl J Med. 2011;364:248–254. [PubMed]
71. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone. 2004;34:303–319. [PMC free article] [PubMed]
72. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280:2543–2549. [PubMed]
73. Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S. Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH. Am J Physiol Renal Physiol. 2010;299:F1212–1217. [PubMed]
74. Saji F, Shiizaki K, Shimada S, Okada T, Kunimoto K, Sakaguchi T, Hatamura I, Shigematsu T. Regulation of fibroblast growth factor 23 production in bone in uremic rats. Nephron Physiol. 2009;111:p59–66. [PubMed]
75. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D. Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology. 2009;150:4835–4845. [PubMed]
76. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, Katayama A, Haba T, Uchida K, Nakanishi S, Kazama JJ, Gejyo F, Yamashita T, Fukagawa M. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis. 2004;44:481–487. [PubMed]
77. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113:561–568. [PMC free article] [PubMed]
78. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98:6500–6505. [PubMed]
79. Shimada T, Takeshita Y, Murohara T, Sasaki K, Egami K, Shintani S, Katsuda Y, Ikeda H, Nabeshima Y, Imaizumi T. Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation. 2004;110:1148–1155. [PubMed]
80. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289:F1088–1095. [PubMed]
81. Shore EM, Ahn J, Jan de Beur S, Li M, Xu M, Gardner RJ, Zasloff MA, Whyte MP, Levine MA, Kaplan FS. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med. 2002;346:99–106. [PubMed]
82. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004;23:421–432. [PMC free article] [PubMed]
83. Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B. Genetic ablation of vitamin d activation pathway reverses biochemical and skeletal anomalies in fgf-23-null animals. Am J Pathol. 2006;169:2161–2170. [PubMed]
84. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Seminars in dialysis. 2007;20:302–308. [PubMed]
85. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol Supplementation Alters Calcitriol-Responsive Monocyte Proteins and Decreases Inflammatory Cytokines in ESRD. J Am Soc Nephrol. 2009 [PubMed]
86. Stubbs JR, Quarles LD. Fibroblast growth factor 23: uremic toxin or innocent bystander in chronic kidney disease? Nephrol News Issues. 2009;23:33–34. 36–37. [PubMed]
87. Takeshita K, Fujimori T, Kurotaki Y, Honjo H, Tsujikawa H, Yasui K, Lee JK, Kamiya K, Kitaichi K, Yamamoto K, Ito M, Kondo T, Iino S, Inden Y, Hirai M, Murohara T, Kodama I, Nabeshima Y. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation. 2004;109:1776–1782. [PubMed]
88. Tebben PJ, Singh RJ, Clarke BL, Kumar R. Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism. Mayo Clin Proc. 2004;79:1508–1513. [PubMed]
89. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006;70:1858–1865. [PubMed]
90. Tomiyama K, Maeda R, Urakawa I, Yamazaki Y, Tanaka T, Ito S, Nabeshima Y, Tomita T, Odori S, Hosoda K, Nakao K, Imura A. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A. 2010;107:1666–1671. [PubMed]
91. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D(3) synthesis in leptin-deficient ob/ob mice. J Bone Miner Res. 2010 [PubMed]
92. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774. [PubMed]
93. Uzum AK, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F, Ozbey NC. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol. 2010;163:825–831. [PubMed]
94. van de Graaf SF, Boullart I, Hoenderop JG, Bindels RJ. Regulation of the epithelial Ca2+ channels TRPV5 and TRPV6 by 1alpha,25-dihydroxy Vitamin D3 and dietary Ca2+ J Steroid Biochem Mol Biol. 2004;89–90:303–308. [PubMed]
95. van Husen M, Fischer AK, Lehnhardt A, Klaassen I, Moller K, Muller-Wiefel DE, Kemper MJ. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int. 2010;78:200–206. [PubMed]
96. Vervloet MG, van Ittersum FJ, Buttler RM, Heijboer AC, Blankenstein MA, Ter Wee PM. Effects of Dietary Phosphate and Calcium Intake on Fibroblast Growth Factor-23. Clin J Am Soc Nephrol. 2010 [PubMed]
97. Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003;18:1227–1234. [PubMed]
98. Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD. Clin J Am Soc Nephrol. 2009 [PubMed]
99. Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nature clinical practice. 2009;5:24–33. [PubMed]
100. Wetmore JB, Santos PW, Mahnken JD, Krebill R, Menard R, Gutta H, Quarles LD. Elevated FGF23 levels are associated with impaired calcium-mediated suppression of PTH in ESRD. J Clin Endocrinol Metab. 2011;96:E57–64. [PubMed]
101. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60:2079–2086. [PubMed]
102. Wolf M. Forging Forward with 10 Burning Questions on FGF23 in Kidney Disease. J Am Soc Nephrol. 2010 [PubMed]
103. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun. 2000;277:494–498. [PubMed]
104. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS) Am J Kidney Dis. 2004;44:34–38. [PubMed]
105. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology. 2005;146:4647–4656. [PubMed]